Skip to main content

Temporary Change in PDL Status for the Tetracycline Drug Class, Effective January 11, 2022

Last updated on

The Texas Health and Human Services Commission (HHSC) has become aware of a drug shortage of Vibramycin 25mg/5mL suspension in the tetracycline drug class because of Pfizer’s discontinuation of the product. HHSC has received reports of a shortage from managed care organizations (MCOs) and verified it on the U.S. Food and Drug Administration drug shortage website. 

In response to the shortage of the preferred brand product Vibramycin 25mg/5mL suspension, national drug code (NDC) 0069-0971-95, HHSC has temporarily removed the non-preferred status from the generic product, doxycycline 25mg/5mL suspension, on the preferred drug list (PDL).

HHSC has removed the non-preferred status of the following drugs, effective January 11, 2022:

NDC

Drug Name

62135-0417-46

DOXYCYCLINE 25 MG/5 ML SUSP

68180-0657-01

DOXYCYCLINE 25 MG/5 ML SUSP

69097-0228-43

DOXYCYCLINE 25 MG/5 ML SUSP

These changes will allow providers to prescribe the generic doxycycline suspension without requiring a PDL prior authorization and continue accessing necessary medication for clients. This is a temporary change until the preferred products are sufficiently available in the market, and HHSC will provide further announcements regarding future PDL status changes for these NDCs.

Email VDP-Formulary@hhsc.state.tx.us with questions or comments.